A 90-day Pharma 4.0 pilot should earn a decision, not just a demo

The signal: people are part of the implementation

The ISPE programme includes workforce adoption and AI transformation topics. Our interpretation is practical: a pilot changes responsibilities as well as software. A scientist may prepare information differently, a reviewer may receive more material and a data owner may inherit a new maintenance task. Those changes belong in the investment decision. [1]

The ninety-day structure below is BioMedAna's suggested planning tool, not an ISPE requirement or a promised delivery timeline. Some organizations will need more time for access, procurement, scientific evidence or validation. The useful feature is the sequence of decisions and evidence, rather than the calendar label.

The pilot changes the operating model, not just the application

A Pharma 4.0 pilot should connect scientific resources, information, organization and culture around one repeated decision. That means changing preparation work, reviewer responsibilities, source ownership, training and support arrangements together. Adoption is demonstrated when the receiving team can perform the workflow and recognize its limits. [4]

Give MSAT, manufacturing, QC, QA and data/system owners a shared brief. State which decision each owns and what evidence would allow the next stage. Reward discovery of a simpler method or a reason to stop. A culture that treats every pilot as a promised success makes it harder to find the failures that matter.

A Pharma 4.0 pilot must earn both scientific trust and organizational adoption. Demonstrate the computational basis, train the receiving team and measure complete operating effort before expansion.THE BIOMEDANA LENS

Start with a constraint the team recognizes

Choose one workflow where the organization can identify a current cost or delay. A hypothetical candidate is preparation for a recurring process investigation: relevant data exist, but a scientist spends substantial effort aligning records before a reviewer can evaluate possible explanations. Specify the receiving decision and the users who perform the work.

Record the baseline using representative cases, including an exception. Define how effort, elapsed time, evidence completeness and reviewer correction will be measured. A single unusually difficult case is a poor universal benchmark. The team should understand what makes cases comparable and what differences will be reported separately.

Days 1-30: establish a feasible evidence path

The first phase should produce an intended-use statement, source inventory, ownership map and small representative dataset. Test whether the evidence can be accessed and interpreted for the selected task. If essential identities cannot be reconciled, treat that as a finding with an owner and a proposed remedy, rather than hiding it behind a demonstration dataset.

Agree the scientific and operating acceptance criteria before optimization begins. Specify which failures prevent continued use and what would count as sufficient evidence to expand. Involve the receiving reviewer early enough to change the design. Training should include recognition of limitations and exceptions, not only navigation through the successful flow.

Days 31-60: compare the complete workflow

Run representative cases with a defined review arrangement. Retain the machine contribution, human correction, source problems and final disposition. Include preparation, maintenance and review time in the comparison. An assistant that drafts quickly but creates extensive checking work may improve one task while worsening the overall process.

Do not let an attractive demonstration redefine the success criterion halfway through the pilot. If the team discovers a more useful adjacent task, record the scope change and the evidence needed for it. A revised pilot can be the right decision, but the final report should explain what was actually tested and which original questions remain unanswered.

Days 61-90: test ownership and failure recovery

Ask a second qualified user to run the workflow from the retained instructions and evidence. Introduce an access failure, a changed source and an unsupported request. Observe whether the operating team can identify the problem, continue appropriately or pause the tool. Founder intervention should not be the hidden dependency that makes every difficult case work.

Prepare a transition record with support ownership, training responsibilities, monitoring, change triggers and exit arrangements. If these are unresolved, wider adoption can amplify the problem. The pilot should reveal the effort required to operate the system after the initial implementation team steps back.

Qualify the work each role will actually do

Training attendance does not show that a team can operate the workflow. Ask an MSAT reviewer to challenge a model outside its demonstrated range. Ask Quality to identify an unsupported conclusion and its approval boundary. Ask IT or the data owner to reconstruct a result and recover from an access or source failure. Ask the sponsor to explain what the evidence justifies funding next.

Record the observed task performance, gaps, support needed and triggers for reassessment. Different responsibilities need different demonstrations; every role does not need to build a model or earn the same literacy score.

Alongside total work and review capacity, choose a workflow-relevant operating measure. This could be timely closure of material exceptions, fewer unresolved transfer questions or a resource-use measure within quality constraints. Treat supply reliability and sustainability improvements as outcomes to establish with data, rather than automatic benefits of installing AI.

Build a business case with explicit assumptions

Separate released capacity, avoided spending and speculative future value. For released capacity, document the observed time difference, eligible case volume and the proportion of that capacity the team can redeploy. Do not count the same time as both labor savings and extra throughput unless the operating assumptions justify both effects.

Include data preparation, integration, reviewer effort, platform costs, maintenance and change evaluation. Use a range where volume or adoption is uncertain. A defensible business case can show that the workflow is scientifically useful but not yet economical at the current volume. That conclusion can prevent an expensive rollout while preserving the learning.

BioMedAna: demonstrate scientific capability and operating adoption together

For BioMedAna, the pilot should demonstrate the parts of its scientific layer that the chosen question requires: connected data, physics-based engineering calculations, chemical reaction modelling, or mechanistic and machine-learning hybrid models. AI agents help coordinate authorized tasks and prepare evidence for review. The proposal should name which services are needed and which add no value to the first use.

Ask the team to change an input, reproduce the relevant numerical result, inspect the source and model basis, challenge the interpretation and carry the accepted next step into its normal operating process. Measure preparation, review, failed attempts, upkeep and recovery. That demonstration differentiates scientific software through what it computes and how people can use it, rather than through an AI label or an unsupported claim about another vendor.

A 90-day pilot investment review

An original BioMedAna working framework. Adapt the decisions and evidence to the actual process, people and intended use.

The questions behind the headline

Follow the evidence

1. ISPE 2026 Annual Meeting & Expo - live agenda, accessed 21 October 2026 ↗
2. ICH Q10 - Pharmaceutical Quality System ↗
3. NIST - AI RMF Playbook; voluntary guidance based on AI RMF 1.0 ↗
4. ISPE - Pharma 4.0 operating model: organizational, cultural, process and resource dimensions ↗

Original BioMedAna editorial analysis. The linked sources support the reported developments; examples, frameworks and product implications reflect our perspective.

Explore the underlying concepts

Explore the ISPE & Pharma 4.0 series ↗

• Where AI creates value in bioprocessing
• Evaluate a bioprocess AI platform
• Enterprise implementation
• Discuss your pilot with BioMedAna